Molecular Typing Of Salmonella Enterica Serovar Typhimurium
Funder
National Health and Medical Research Council
Funding Amount
$272,545.00
Summary
Salmonella mainly causes food poisoning and is a significant human health problem. Different Samonella forms are identified by serotyping and many serovars have been given a name . There are more than 2000 serovars. The best known serovar is Typhimurium which is the cause of 40% of salmonella infections. Typhimurium is so frequently involved in infections it is necessary to further divide it for outbreak investigations and long term monitoring of the organism. The only widely used method to subd ....Salmonella mainly causes food poisoning and is a significant human health problem. Different Samonella forms are identified by serotyping and many serovars have been given a name . There are more than 2000 serovars. The best known serovar is Typhimurium which is the cause of 40% of salmonella infections. Typhimurium is so frequently involved in infections it is necessary to further divide it for outbreak investigations and long term monitoring of the organism. The only widely used method to subdivide Typhimurium is phage typing, which is done only in major laboratories (2 in Australia). Phage typing is based on lysis patterns of a test isolate to a set of 34 phages. Phage typing has played a crucial role in tracking the organism, for example the emergence of a multidrug resistance new type (DT204c) in UK and US. The technique is simple but the problem is that reactions vary with slight change in conditions and scoring the reaction results is very subjective. We propose to replace the typing system with one based on the DNA method PCR, so it will be simple, fast and accurate. We will use a DNA fingerprinting technique called AFLP (amplified fragment length polymorphism) to find markers (DNA segments) that are specific to phage types and design PCR assays based on the markers we find. Such a typing system will retain the essence of phage typing by providing continuity of the valuable epidemiological database on phage types. Further the typing system could easily be expanded to accommodate any new types by finding more markers while the current phage typing system is very difficult to expand (last done in 1977 and is behind in our needs). This project will establish a general approach for designing typing systems based on molecular biology for other pathogens and could have a major impact on the surveillance of bacterial infections in the 21st century.Read moreRead less
Optimising Temporal Genomic Surveillance Of Salmonella Infections In Australia
Funder
National Health and Medical Research Council
Funding Amount
$763,447.00
Summary
Salmonella is a leading cause of the food-borne disease – salmonellosis. It is responsible for considerable morbidity and has an enormous economic cost. Molecular typing is the key to rapidly identify and control outbreaks. This project will optimise the use of whole genome sequencing for outbreak investigation and long term epidemiology. A surveillance system that integrates genome sequence and epidemiological data will be highly significant for outbreak investigation and disease prevention.
Monoclonal antibodies, such as the cancer therapeutic Pembrolizumab, have revolutionised the treatment of cancer and many inflammatory conditions. With over $100 billion in sales in 2018, they also underpin a growing biotech industry. We have developed a highly specific, high affinity therapeutic antibody candidate, and demonstrated efficacy in animal models of malignancy. This project will advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
An Investigation Into The Role Of 3’UTR Dynamics In Breast Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$627,444.00
Summary
Basic research has brought many improvements to the diagnosis and treatment of cancer. An exception are the triple negative breast cancers. No targeted therapies yet exist, and thus a combination of chemotherapy, surgery and radiation therapy is the only option. For 2/3rds of women this works well and survivor rates are high, but the prognosis is poor for those that do not respond. This research aims to reveal therapeutic opportunities to block the potential of such tumours to spread.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.